Caplin Point Laboratories Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Caplin Point Laboratories Ltd. authored by FundsIndia and published by - Trendlyne research reports.
Item: Caplin Point Laboratories Ltd.
Rating: 5
Author: FundsIndia

Keep track of all breaking news and updates on Caplin Point Laboratories Ltd. from all sources in a single place.

Caplin Point Laboratories Ltd.

03 Sep 2025

2321.50

-0.37%

Caplin Point's unit gets USFDA nod for generic milrinone lactate injection

Business Standard

Pharma firm Caplin Point Laboratories Ltd on Wednesday said its arm Caplin Steriles Ltd has received final approval from the US health regulator for its generic milrinone lactate in 5 per cent dextrose injection indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. The approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) milrinone lactate in 5 per cent Dextrose Injection of strengths 20 mg/100 mL and 40 mg/200 mL in single-dose infusion bags, Caplin Point Laboratories said in a regulatory filing. The approved injection is a generic therapeutic equivalent version of the reference listed drug PRIMACOR in dextrose 5 per cent, by Sanofi Aventis US LLC, it added. Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure, the company said. Citing IQVIA (IMS Health) data, the company said milrinone lactate in 5 per cent...

Caplin Point Laboratories Ltd. is trading above all available SMAs

Caplin Point Laboratories Ltd.

03 Sep 2025

2321.50

-0.37%

Company Update

Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press release - Receipt of USFDA Approval

pdf

Caplin Point Laboratories Ltd.

01 Sep 2025

2321.50

-0.37%

Company Update

Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper publication on Notice of 34th Annual General Meeting of the Company along with e-voting information

pdf

Caplin Point Laboratories Ltd.

30 Aug 2025

2321.50

-0.37%

Corp. Note

Caplin Point Laboratories Ltd - 524742 - Business Responsibility and Sustainability Reporting (BRSR)

BSE India

Business Responsibility and Sustainability Reporting for the Financial Year 2024-25

pdf

Caplin Point Laboratories Ltd.

30 Aug 2025

2321.50

-0.37%

AGM

Caplin Point Laboratories Ltd - 524742 - Notice Of 34Th Annual General Meeting Of The Company

BSE India

Notice of 34th Annual General Meeting of the Company

pdf

Caplin Point Laboratories Ltd.

30 Aug 2025

2321.50

-0.37%

Corp. Note

Caplin Point Laboratories Ltd - 524742 - Reg. 34 (1) Annual Report.

BSE India

Annual Report for the Financial Year ended March 31, 2025 - Regulation 34(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

pdf

Caplin Point Laboratories Ltd.

22 Aug 2025

2321.50

-0.37%

Stock Market Live Updates 22 August 2025: Stock to buy today: Caplin Point Laboratories

Business Line

Sensex, Nifty, Share Prices LIVE: The short-term outlook is bullish for Caplin Point Laboratories. The 4 per cent rise has taken the share price well above the 2,130-2,140 resistance zone. This region will now act as a good support and limit the downside. Below this 2,080 will be the next important support. Immediate resistance is at 2,230 which can be broken in the next few days. Such a break can take Caplin Point Laboratories share price up to 2,330 in the coming weeks. Traders can buy Caplin Point Laboratories now at 2,205. Accumulate on dips at 2,160. Keep the stop-loss at 2,110 initially. Trail the stop-loss up to 2,225 as soon as the stock goes up to 2,255. Move the stop-loss further up to 2,260 and 2,285 when the price touches 2,280 and 2,300 respectively. Exit the long positions at 2,320.